Wild-type HLA-presented peptides

Wild-type HLA-presented peptides are non-mutated protein fragments displayed on the cell surface by Human Leukocyte Antigen (HLA) molecules, representing the 'self' immunopeptidome (Bassani-Sternberg et al., 2016, Nature Communications). These peptides are essential for maintaining immune tolerance, as the immune system is trained to recognize them as 'self' and avoid mounting an attack (Murphy & Weaver, 2016, Janeway's Immunobiology). In the development of cancer immunotherapies, such as TCR-T cell therapies or neoantigen vaccines, these wild-type counterparts serve as critical safety benchmarks to ensure that the treatment does not cross-react with healthy tissues (Schumacher & Schreiber, 2015, Science). If a drug fails to distinguish between a tumor-specific mutation and its wild-type counterpart, it can lead to severe 'on-target, off-tumor' toxicity, potentially causing organ damage or death (Linette et al., 2013, Blood). Therefore, while not typically the intended therapeutic target, these peptides are central to the safety profiling and specificity testing of modern biologics (Johnson et al., 2009, Blood). Their identification via mass spectrometry and computational modeling is a standard step in modern drug discovery pipelines (Caron et al., 2015, Molecular & Cellular Proteomics).

Other names

Self-antigensNon-mutated HLA ligandsWild-type epitopesNormal tissue antigensWild-type counterparts of neoantigensWT-pMHC

These peptides do not typically serve as the intended target for drug action; instead, they function as essential safety filters during the development of TCR-based and vaccine therapies to ensure that the immune response is restricted to mutated or overexpressed antigens and does not attack healthy cells expressing wild-type sequences (Schumacher & Schreiber, 2015, Science).